Table 3 Comparison of various combinations of cytokines as predictors of clinical progression in ANA+ subjects lacking a SARD diagnosis
Cytokine combination | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|
Galectin-9 (≥ 2914 pg/mL) | 69.23 | 73.81 | 45.00 | 88.57 |
CXCL-10 (≥ 689 pg/mL) | 61.54 | 85.71 | 57.14 | 87.80 |
IFN-α (≥ 0.91 pg/mL) | 53.85 | 83.33 | 50.00 | 85.37 |
CXCL-10 and Galectin-9 | 53.85 | 88.10 | 58.33 | 86.05 |
Galectin-9 and IFN-α | 46.15 | 97.62 | 85.71 | 85.42 |
CXCL-10 and IFN-α | 46.15 | 100.00 | 100.00 | 85.71 |
RO52 (≥ 11.87 NFI) | 75.00 | 71.79 | 45.00 | 90.32 |
RO52 and Galectin-9 | 58.33 | 92.31 | 70.00 | 87.80 |
RO52 and CXCL-10 | 50.00 | 92.31 | 66.67 | 85.71 |
RO52 and IFN-α | 58.33 | 87.18 | 58.33 | 87.18 |
RO52 and CXCL-10 and Galectin-9 | 50.00 | 94.87 | 75.00 | 86.05 |
RO52 and Galectin-9 and IFN-α | 50.00 | 97.44 | 85.71 | 86.36 |
RO52 and CXCL-10 and IFN-α | 46.15 | 100.00 | 100.00 | 85.71 |
RO52 and CXCL-10 and Galectin-9 and IFN-α | 46.15 | 100.00 | 100.00 | 85.71 |